Free Trial

Q3 EPS Forecast for Ovid Therapeutics Reduced by Analyst

Ovid Therapeutics logo with Medical background

Key Points

  • Wedbush Research lowered Ovid Therapeutics' Q3 2025 earnings per share (EPS) estimate from (0.14) to (0.15), with a full-year consensus estimate at (0.40).
  • Ovid Therapeutics reported earnings of (0.06) per share for the latest quarter, exceeding consensus estimates by $0.10, despite a negative return on equity of 58.87%.
  • Various analysts have differing ratings for Ovid Therapeutics, with the stock holding a consensus rating of "Buy" and an average target price of $3.10.
  • Need better tools to track Ovid Therapeutics? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

Ovid Therapeutics (NASDAQ:OVID - Free Report) - Stock analysts at Wedbush lowered their Q3 2025 earnings per share (EPS) estimates for Ovid Therapeutics in a research note issued to investors on Wednesday, August 13th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($0.15) per share for the quarter, down from their prior estimate of ($0.14). The consensus estimate for Ovid Therapeutics' current full-year earnings is ($0.40) per share. Wedbush also issued estimates for Ovid Therapeutics' FY2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.14) EPS and FY2026 earnings at ($0.53) EPS.

Ovid Therapeutics (NASDAQ:OVID - Get Free Report) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.10. Ovid Therapeutics had a negative return on equity of 58.87% and a negative net margin of 574.44%.The business had revenue of $6.27 million for the quarter, compared to analysts' expectations of $0.09 million.

Several other brokerages have also recently issued reports on OVID. HC Wainwright decreased their target price on shares of Ovid Therapeutics from $2.00 to $1.50 and set a "buy" rating on the stock in a research report on Tuesday, May 27th. Wall Street Zen raised Ovid Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. William Blair upgraded Ovid Therapeutics to a "strong-buy" rating in a research report on Thursday, April 24th. Finally, B. Riley reissued a "buy" rating and issued a $3.00 price objective on shares of Ovid Therapeutics in a research note on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $3.10.

Get Our Latest Report on OVID

Ovid Therapeutics Price Performance

Ovid Therapeutics stock traded down $0.0140 during mid-day trading on Monday, reaching $0.9360. 530,099 shares of the company's stock traded hands, compared to its average volume of 967,490. Ovid Therapeutics has a 12-month low of $0.2425 and a 12-month high of $1.47. The company has a quick ratio of 4.72, a current ratio of 4.72 and a debt-to-equity ratio of 0.23. The stock has a 50 day moving average of $0.49 and a two-hundred day moving average of $0.43. The company has a market cap of $66.56 million, a price-to-earnings ratio of -1.77 and a beta of 0.20.

Hedge Funds Weigh In On Ovid Therapeutics

Large investors have recently made changes to their positions in the business. Renaissance Technologies LLC increased its position in Ovid Therapeutics by 142.0% during the 4th quarter. Renaissance Technologies LLC now owns 107,700 shares of the company's stock valued at $101,000 after buying an additional 63,200 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new stake in Ovid Therapeutics in the fourth quarter valued at $934,000. Bank of America Corp DE grew its holdings in Ovid Therapeutics by 49.7% during the fourth quarter. Bank of America Corp DE now owns 56,733 shares of the company's stock worth $53,000 after acquiring an additional 18,841 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in shares of Ovid Therapeutics during the 4th quarter valued at approximately $272,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Ovid Therapeutics by 50.2% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 943,416 shares of the company's stock valued at $881,000 after purchasing an additional 315,126 shares during the period. 72.24% of the stock is owned by institutional investors and hedge funds.

Ovid Therapeutics Company Profile

(Get Free Report)

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.

Read More

Earnings History and Estimates for Ovid Therapeutics (NASDAQ:OVID)

Should You Invest $1,000 in Ovid Therapeutics Right Now?

Before you consider Ovid Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ovid Therapeutics wasn't on the list.

While Ovid Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Next Tech Boom: AI Robots Are Coming Sooner Than You Think!
Tech Stocks Stumble: Will Nvidia’s Report Spark a Rebound?
Follow the Money: 5 Stocks Institutions Are Buying NOW

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines